[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"psp---progressive-supranuclear-palsy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:psp---progressive-supranuclear-palsy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,69,122],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100613261","phase-2-the-progressive-supranuclear-palsy-clinical-trial-platform---regimen-b-lm11a-31-100613261",false,"NCT07264283","The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31","Inclusion Criteria:\n\n1. Clinical diagnosis of possible or probable PSP Richardson's Syndrome as defined by the 2017 Movement Disorder Society (MDS) criteria.\n2. Presence of PSP symptoms for ≤5 years at screening (based on the best judgment of the site PI).\n3. Mini-Mental State Examination (MMSE) score at screening of ≥25.\n4. Able to walk at least 10 steps with minimal assistance (e.g., one arm for safety, but not postural support).\n5. Stable doses of permitted medications as described per protocol for 30 days prior to screening.\n6. Resides at home or in the community (assisted living is acceptable).\n7. As assessed by the site PI, participant is likely to be able to comply with the protocol for the duration of the study, and has adequate vision, hearing (hearing aid permitted), and literacy (English or Spanish) sufficient for compliance with the required testing procedures.\n\nExclusion Criteria:\n\n1. Females who are breastfeeding or pregnant (as documented by a urine pregnancy test) during screening, or plan to become pregnant during the study.\n2. Females of childbearing potential who did not use a highly effective method of contraception within 28 days of screening and\u002For are not willing to use a highly effective method of contraception for the duration of their participation in the study.\n3. Lacks good venous access such that multiple blood draws would be precluded.\n4. Weighs less than 40kg, or more than 136kg at screening.\n5. Blood transfusion within 4 weeks of screening.\n6. Contraindications to MRI studies, including metal (ferromagnetic) implants, a cardiac pacemaker that is not compatible with MRI, and\u002For severe claustrophobia.\n7. Screening MRI scan showing structural evidence of alternative pathology not consistent with PSP that could explain a substantial portion of the participant's symptoms as indicated by the central MRI read.\n8. Any unstable and\u002For clinically significant medical condition likely to hamper the evaluation of safety and\u002For efficacy of study drug (e.g., clinically significant reduction in serum B12 or folate levels, clinically significant abnormalities of thyroid function, stroke, or other cerebrovascular or cardiovascular conditions), as per the site PI's judgment.\n9. History of severe allergic reaction (e.g., anaphylaxis) including but not limited to: severe allergic reaction to previous vaccines, foods, and\u002For medications.\n10. Hospitalization within 30 days prior to screening or baseline.\n11. Infections or major surgical procedures within 3 months prior to screening, judged to be clinically significant by the site PI.\n12. Myocardial infarction within 1 year prior to baseline, unstable angina pectoris, symptomatic congestive heart failure.\n13. History of cancer within the past 5 years other than treated skin squamous cell carcinoma, basal cell carcinoma, and melanoma in-situ, localized prostate cancer not requiring treatment, or prostate or breast cancer, which have been fully removed and are considered cured.\n14. History or presence of immunological or inflammatory conditions, including neurological disorders, meningitis or meningoencephalitis.\n15. History or presence of epilepsy requiring ongoing use of antiepileptic medications. Antiepileptic medications are permitted for pain or psychiatric use per the protocol.\n16. DSM-5 criteria for drug or alcohol abuse or dependence currently met within the past 5 years.\n17. Clinically significant abnormal vital signs including sustained sitting blood pressure \\>160\u002F100 mm Hg.\n18. Diabetes mellitus with hemoglobin A1c (HbA1c) levels of ≥8.0%.\n19. Known history of human immunodeficiency virus (HIV-1 or 2).\n20. Known history of acute\u002Fchronic hepatitis B or C unless treated curatively.","ALL","41 Years","86 Years",{"count":19,"type":20},147,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP. Regimen B will evaluate the safety and efficacy of a single study drug, LM11A-31, in participants with PSP.",[26],"PSP - Progressive Supranuclear Palsy",[28,29,30,31,32,33,34,35,36,37],"PSP","Placebo-Controlled","Double-Blind","Regimen Specific Appendix","LM11A-31","Tau Protein","Oral treatment","Disease modifying","P75 neurotrophin receptor","Synaptic resilience","NOT_YET_RECRUITING","2026-04-24",{"date":41,"type":42},"2026-04-27","ACTUAL",{"date":44,"type":20},"2026-06-30",{"date":46,"type":20},"2030-09-28",{"name":48,"class":49},"Adam Boxer","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":68,"locationsCount":4},"100609675","phase-2-the-progressive-supranuclear-palsy-clinical-trial-platform---regimen-a-aadvac1-100609675","NCT07217665","The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1",{"count":56,"type":20},146,[23],"The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP.\n\nRegimen A will evaluate the safety and efficacy of a single study drug, AADvac1, in participants with PSP.",[26],[28,29,30,31,61,62,63,64],"AADvac1","Vaccine","Tau protein","Immunotherapy",{"date":41,"type":42},{"date":44,"type":20},{"date":46,"type":20},{"name":48,"class":49},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":15,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":83,"conditions":84,"keywords":94,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100632087","ultra-high-resolution-pet-in-aging-neurodegeneration-and-psychotic-disorders-100632087","NCT07509125","Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders","Ultra-High Resolution PET of the Human Brain and Spinal Cord in Healthy Aging, Dementia, Movement Disorders, ALS and Psychotic Disorders","Inclusion Criteria:\n\n* WP1: Healthy controls\n* Age between 18 and 90 years old (15 aged 18-50 years and 25 aged 50 90 years);\n* Subject is judged to be in good health by the investigator on the basis of medical history, physical examination including vital signs and clinical laboratory tests;\n* No history or evidence of current major neurological, internal or psychiatric disorder, based on the medical assessment as described hereabove and neuropsychological assessment;\n* No evidence of cognitive impairment as assessed by a Montreal Cognitive Assessment (MoCA) score of 26 or higher at baseline;\n* In subjects \\\u003C 60 years of age, a normal structural MRI scan as assessed by expert radiologist.\n* In subjects \\>= 60 years of age white matter hyperintensities corresponding to a WML (white matter lesion) score \\\u003C= 2 (of 3) on the Age-Related White Matter changes scale are acceptable;\n* When older than 50 years of age, the volunteer is willing to undergo a p- tau217 blood sample.\n* WP2: Dementia\n* Patient has a clinical diagnosis of biomarker-proven prodromal AD\n* WP3: ALS spectrum\n* Subject must meet El Escorial Criteria (30) and Awaji-Shima criteria (31) for at least possible ALS;\n* WP4: Movement disorders\n* (all): Patient (or legal representative, when applicable) is able to understand the patient information form and give written informed consent.\n* Parkinson´s disease (PD):\n* Patient has clinically established PD based on the Movement Disorder Society (MDS) diagnostic criteria (32);\n* Patient has an abnormal 18F-PE2I PET;\n* No evidence of cognitive impairment as assessed by a Montreal Cognitive Assessment (MoCA) score of 26 or higher at baseline.\n* Multiple system atrophy (MSA)\n* Patient has clinically established or clinically probable MSA-P based on the\n* Movement Disorder Society (MDS) diagnostic criteria (33);\n* Patient has an abnormal 18F-PE2I PET.\n* Progressive supranuclear palsy (PSP)\n* Patient has an abnormal 18F-PE2I PET;\n* Patient has clinically established probable PSP according to the latest MDS criteria\n* Dementia with Lewy bodies (DLB)\n* Patient has probable DLB by consensus criteria (cognitive impairment MoCA \\\u003C 26 + visual hallucinations and\u002For fluctuating alertness);\n* Patient has an abnormal 18F-PE2I PET.\n* Idiopathic REM sleep behavior disorder (iRBD)\n* Patient has Polysomnography-confirmed iRBD;\n* No evidence of cognitive impairment as assessed by a Montreal Cognitive Assessment (MoCA) score of 26 or higher at baseline;\n* No clinical evidence of parkinsonism at baseline.\n* WP5: Psychosis\n* DSM 5 criteria for a non-affective schizophrenia spectrum psychotic disorder;\n* Age between 18 and 55 years old for adult-onset psychosis, onset of psychosis (and age) above 60 years old for very late onset psychosis.\n\nExclusion Criteria:\n\n* Subject has a history of any major (other) internal, psychiatric or neurological disease that may interfere with the investigations (especially liver and kidney disease, uncontrolled diabetes, cancer, severe depression, stroke, severe TBI);\n* Subject is currently a user (including recreational use) of any illicit drugs, including cannabis, or has a history of drug or alcohol abuse;\n* Subject chronically uses medication that has central nervous system effects (e.g. strong painkillers such as opioids, neuroleptics,..; ) (other than prescribed for the illness in case of patients);\n* Subject has had exposure to ionizing radiation (\\> 1 mSv) in other research studies within the last 12 months;\n* Subject has a contra-indication for MRI scanning;\n* Subject suffers from claustrophobia or cannot tolerate confinement during PET-MRI scanning procedures; subject cannot lie still for (at least) 60 minutes inside the scanner;\n* (For subjects with arterial sampling): The subject is hypersensitive to lidocaine (used for local anaesthesia during the placement of the arterial catheter), has an abnormal Allen test (a test to check blood flow in the arteries of the forearm) or is on anti-coagulant therapy;\n* Subject (or his\u002Fher legal representative) does not understand the study procedures;\n* Subject is unwilling or unable to perform all of the study procedures, or is considered unsuitable in any way by the principal investigator;\n* Subject is potentially pregnant (hCG test can be done if doubt exists).",true,"18 Years","90 Years",{"count":80,"type":20},300,[82],"NA","The goal of this study is to use ultra-high-resolution (UHR) PET imaging to better understand how the brain and spinal cord change in healthy aging and in neurological and psychiatric disorders such as Alzheimer's disease (AD), Parkinson's disease and related movement disorders, amyotrophic lateral sclerosis (ALS), and psychotic disorders. Researchers will use the NeuroExplorer PET\u002FCT system, a new scanner that can show very small structures in the brain and spinal cord in much more detail than regular PET.\n\nThe main questions this study aims to answer are:\n\n* How do small but important brain regions (like the locus coeruleus, substantia nigra, and thalamic nuclei) change in healthy aging?\n* What early brain changes occur in neurodegenerative and psychotic disorders, and can they help improve early diagnosis?\n\nParticipants will:\n\n* Undergo PET and MRI brain scans using different tracers that measure brain metabolism (18F-FDG), synaptic density (¹⁸F-SynVesT-1), dopamine transporters (¹⁸F-PE2I), and tau protein buildup (¹⁸F-MK6240).\n* Complete cognitive and clinical assessments related to memory, mood, and motor or psychiatric symptoms, depending on their group.\n\nThis study will include healthy volunteers and patients with mild cognitive impairment due to Alzheimer´s disease, ALS, Parkinson's disease and related disorders, or psychotic disorders.\n\nThe results will help create detailed brain imaging maps for healthy aging and identify early biomarkers for different diseases to support better diagnosis and treatment in the future.",[85,86,87,88,26,89,90,91,92,93],"Alzheimer Dementia (AD)","ALS - Amyotrophic Lateral Sclerosis","Parkinson s Disease","REM Sleep Behavior Disorder (iRBD)","MSA - Multiple System Atrophy","Dementia With Lewy Bodies (DLB)","ALS With Frontotemporal Dementia (ALS\u002FFTD)","Adult Onset Psychotic Disorder","Very Late Onset Psychotic Disorder",[95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110],"PET\u002FCT scan","Alzheimer´s disease","Dementia","Amyotrophic Lateral Sclerosis","Parkinson´s disease","REM sleep behavior disorders","Progressive supranuclear palsy","Multiple System Atrophy","Dementia with Lewy Bodies","Psychotic disorders","Schizophrenia","ALS with frontotemporal dementia","UHR PET","Locus coeruleus","Papez circuit","Thalamic subnuclei","RECRUITING","2026-03-27",{"date":114,"type":42},"2026-04-03",{"date":116,"type":42},"2026-02-13",{"date":118,"type":20},"2029-09",{"name":120,"class":49},"Universitaire Ziekenhuizen KU Leuven",1,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":76,"sex":15,"minAge":128,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":132,"conditions":133,"keywords":150,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":121},"100565858","the-curepsp-genetics-program-100565858","NCT06647641","The CurePSP Genetics Program","Inclusion Criteria:\n\n1. Adults (aged 35 or older) with a clinical diagnosis of PSP, CBS, MSA, or a related neurological disease as confirmed by their healthcare provider, or unaffected family members of participants who have reported a family history of relevant neurodegenerative conditions.\n2. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Possible or Probable PSP (32), clinically established or clinically probable MSA (33), Armstrong criteria (2013) for possible or probable CBS (34). Diagnostic certainty will be determined by the treating\u002Freferring clinician.\n3. Willingness to undergo genetic testing. Participants will have the option to receive relevant genetic test results.\n4. Have the capacity to give full informed consent in writing or electronically, or provide consent through a legally authorized representative (LAR)\u002Fpower of attorney (POA), and have read, understood, and completed the informed consent form.\n5. Are able to perform or have a designee who can perform study activities (including completion of either online or orally administered surveys).\n\nExclusion Criteria:\n\n1. Individuals who have received a blood transfusion within the past 3 months.\n2. Individuals who have active hematologic malignancies such as lymphoma or leukemia.\n3. Individuals who have had a bone marrow transplant within the past 5 years.\n4. Individuals under the age of 35 or age of majority in applicable states at the time of consenting.","35 Years",{"count":130,"type":20},1000,"OBSERVATIONAL","This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families.\n\nUp to 1,000 adults who have been clinically diagnosed with PSP, CBS, MSA, or related neurological conditions will be enrolled. The study intervention involves sequencing of participant blood samples using non-CLIA-approved whole genome sequencing at the National Institutes of Health. Pathogenic variants that are deemed possibly related to these conditions will be confirmed using CLIA-approved testing. The study involves minimal risk to participants.",[28,26,134,135,136,137,138,139,140,89,141,102,142,143,144,145,146,147,148,149],"Corticobasal Syndrome","Corticobasal Syndrome(CBS)","Corticobasal Degeneration Syndrome","Corticobasal Degeneration","Corticobasal Degeneration (CBD)","Corticobasal Syndrome (CBS)","MSA","MSA-C","Multiple System Atrophy (MSA) With Orthostatic Hypotension","Multiple System Atrophy - Cerebellar Subtype (MSA-C)","Multiple System Atrophy - Parkinsonian Subtype (MSA-P)","Multiple System Atrophy, Cerebellar Type","Multiple System Atrophy, Parkinsonian Type","Progressive Supranuclear Palsy","Progressive Supranuclear Palsy(PSP)","Progressive Supranuclear Palsy (PSP)",[151,147,102,152,153,28,140,154,155],"genetic study","Corticobasal","CurePSP","CBD","Genes","2026-01-12",{"date":158,"type":42},"2026-01-14",{"date":160,"type":42},"2024-10-08",{"date":162,"type":20},"2030-12-31",{"name":164,"class":49},"Massachusetts General Hospital"]